Inhibition of sPLA 2 and Endothelial Function: A Substudy of the SPIDER-PCI Trial

Canadian Journal of Cardiology

Volumn 28, Issue 2, 2012, Pages 215-221

  Lavi, Shahar ^a,b   Thorpe, Kevin ^c   Luca, Mary Clare ^c,d   Liuni, Andrew ^c,d   Floras, John ^c,d,e   Horlick, Eric M ^c,e   Ing, Douglas ^c,e   Osten, Mark D ^c,e   Overgaard, Christopher B ^c,e   Lan, Julie ^c,e   Parker, John D ^c,d,e   Cantor, Warren J ^c,f   Džavík, Vladimír ^d,e  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; PHOSPHOLIPASE A2; PLACEBO; VARESPLADIB; ACETIC ACID DERIVATIVE; ENZYME INHIBITOR; INDOLE DERIVATIVE; SECRETORY PHOSPHOLIPASE A2;

ADULT; ARTICLE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY FLOW RESERVE; ENDOTHELIAL FUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FLOW MEDIATED DILATION; GUIDE WIRE; HUMAN; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; VASOMOTOR REFLEX; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DRUG EFFECT; ENZYMOLOGY; FLOW KINETICS; INFLAMMATION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR ENDOTHELIUM;

ACETIC ACIDS; AGED; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; INFLAMMATION; MALE; MIDDLE AGED; PHOSPHOLIPASES A2, SECRETORY; PROSPECTIVE STUDIES; RHEOLOGY;

EID: 84858619547     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2011.11.007     Document Type: Article

References (36)

1. Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003, 23:168-175.
2. Gokce N., Keaney J.F., Hunter L.M., et al. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002, 105:1567-1572.
3. Lavi S., Prasad A., Yang E.H., et al. Smoking is associated with epicardial coronary endothelial dysfunction and elevated white blood cell count in patients with chest pain and early coronary artery disease. Circulation 2007, 115:2621-2627.
4. Widlansky M.E., Gokce N., Keaney J., John F., Vita J.A. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003, 42:1149-1160.
5. Suwaidi J.A., Hamasaki S., Higano S.T., et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000, 101:948-954.
6. Goldberg A., Zinder O., Zdorovyak A., et al. Diagnostic coronary angiography induces a systemic inflammatory response in patients with stable angina. Am Heart J 2003, 146:819-823.
7. Lavi S., Gruberg L. Significance of elevated cardiac troponin after percutaneous coronary interventions. Minerva Cardioangiol 2003, 51:513-523.
8. Hurt-Camejo E., Camejo G., Peilot H., Oorni K., Kovanen P. Phospholipase A2 in vascular disease. Circ Res 2001, 89:298-304.
9. Mallat Z., Benessiano J., Simon T., et al. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the Epic-Norfolk study. Arterioscler Thromb Vasc Biol 2007, 27:1177-1183.
10. Koenig W., Vossen C.Y., Mallat Z., et al. Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. Eur Heart J 2009, 30:2742-2748.
11. Liu P.Y., Li Y.H., Tsai W.C., et al. Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J 2003, 24:1824-1832.
12. Fichtlscherer S., Kaszkin M., Breuer S., Dimmeler S., Zeiher A.M. Elevated secretory non-pancreatic type II phospholipase A2 serum activity is associated with impaired endothelial vasodilator function in patients with coronary artery disease. Clin Sci 2004, 106:511-517.
13. Leite J.O., Vaishnav U., Puglisi M., et al. A-002 (varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs. BMC Cardiovasc Disord 2009, 9:7.
14. van Dijk A., Krijnen P.A., Vermond R.A., et al. Inhibition of type 2A secretory phospholipase A2 reduces death of cardiomyocytes in acute myocardial infarction. Apoptosis 2009, 14:753-763.
15. Rosenson R.S., Hislop C., McConnell D., et al. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (plasma study): a phase II double-blind, randomised, placebo-controlled trial. Lancet 2009, 373:649-658.
16. Dzavik V., Lavi S., Thorpe K., et al. The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDER-PCI) trial. Circulation 2010, 122:2411-2418.
17. Fraser H., Hislop C., Christie R.M., et al. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice. J Cardiovasc Pharmacol 2009, 53:60-65.
18. Dragoni S., Gori T., Lisi M., et al. Pentaerythrityl tetranitrate and nitroglycerin, but not isosorbide mononitrate, prevent endothelial dysfunction induced by ischemia and reperfusion. Arterioscler Thromb Vasc Biol 2007, 27:1955-1959.
19. Gori T., Grotti S., Dragoni S., et al. Assessment of vascular function: flow-mediated constriction complements the information of flow-mediated dilatation. Heart 2010, 96:141-147.
20. Lavi S., McConnell J.P., Rihal C.S., et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 2007, 115:2715-2721.
21. Rosenson R.S., Hislop C., Elliott M., et al. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J Am Coll Cardiol 2010, 56:1079-1088.
22. Vickers A.J., Altman D.G. Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ 2001, 323:1123-1124.
23. Corson M.A. Phospholipase A2 inhibitors in atherosclerosis: the race is on. Lancet 2009, 373:608-610.
24. Thompson A., Gao P., Orfei L., et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010, 375:1536-1544.
25. Tsimikas S., Willeit J., Knoflach M., et al. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J 2009, 30:107-115.
26. de Beer F.C., Webb N.R. Inflammation and atherosclerosis: group IIa and group V sPLA2 are not redundant. Arterioscler Thromb Vasc Biol 2006, 26:1421-1422.
27. Lavi S., Herrmann J., Lavi R., et al. Role of lipoprotein-associated phospholipase A2 in atherosclerosis. Curr Atheroscler Rep 2008, 10:230-235.
28. Yang E.H., McConnell J.P., Lennon R.J., et al. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 2006, 26:106-111.
29. Boekholdt S.M., Keller T.T., Wareham N.J., et al. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the Epic-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 2005, 25:839-846.
30. Spiro J.R., Digby J.E., Ghimire G., et al. Brachial artery low-flow-mediated constriction is increased early after coronary intervention and reduces during recovery after acute coronary syndrome: characterization of a recently described index of vascular function. Eur Heart J 2011, 32:856-866.
31. Liuni A., Luca M.C., Gori T., Parker J.D. Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism. J Am Coll Cardiol 2010, 55:1002-1006.
32. Domoki F., Zimmermann A., Lenti L., et al. Secretory phospholipase A2 inhibitor PX-18 preserves microvascular reactivity after cerebral ischemia in piglets. Microvasc Res 2009, 78:212-217.
33. Lonn E. Lipoprotein-associated phospholipase A2: a new therapeutic target. Can J Cardiol 2010, 26(suppl A):27A-31A.
34. Rastogi P., Beckett C.S., McHowat J. Prostaglandin production in human coronary artery endothelial cells is modulated differentially by selective phospholipase A(2) inhibitors. Prostaglandins Leukot Essent Fatty Acids 2007, 76:205-212.
35. Serruys P.W., Garcia-Garcia H.M., Buszman P., et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008, 118:1172-1182.
36. DeMaria A.N., Narula J., Mahmud E., Tsimikas S. Imaging vulnerable plaque by ultrasound. J Am Coll Cardiol 2006, 47:C32-C39.